In this issue:
- DOACs vs. LMWH: recurrent VTE in patients with cancer
- Long-term mortality after PE
- Indefinite anticoagulant therapy for first unprovoked VTE
- Incidence of VTE in obstructive sleep apnoea
- Biomarker profiles predict cognitive deficits after COVID-19
- Cardiopulmonary exercise testing after acute PE
- Sotatercept for PAH
- Dapagliflozin in HF with mildly reduced/preserved ejection fraction
- Empagliflozin in HF with preserved ejection fraction
- Patients’ perceptions of clinical trial outcomes for PAH therapy
Please login below to download this issue (PDF)